시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 항체 생산 시장 보고서(2025년)
Antibody Production Global Market Report 2025
상품코드 : 1889297
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,559,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,481,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,403,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

항체 생산 시장 규모는 최근 급속히 확대되고 있습니다. 2024년 222억 9,000만 달러로 평가되었고, 2025년에는 258억 9,000만 달러에 달할 것으로 추정되며, CAGR 16.2%로 성장할 전망입니다. 지금까지의 성장은 바이오의약품의 세계 수요 증가, 감염증의 만연 확대, 면역요법의 이점에 대한 인식 증가, 항체 연구 기관의 확대, 항체 기반 진단법의 보급 확대 등이 요인으로 보입니다.

항체 생산 시장 규모는 향후 수년간 급속한 성장이 예상되고 있습니다. 2029년에는 465억 4,000만 달러에 달할 것으로 예측되며, CAGR 15.8%로 성장이 전망됩니다. 예측 기간에 있어서의 성장요인으로는 항체 생산에서 자동화의 진전, 신규 치료용 항체에 대한 주목의 고조, 수탁 제조 파트너십 확대, 신흥 시장에서의 수요 증가 등을 들 수 있습니다. 예측 기간 중 예상되는 주요 동향으로는 항체 정제 기술의 혁신, 항체 약제 복합체(ADC)의 진보, 다특이성 항체 플랫폼의 개발, 항체의 반감기 연장을 목적으로 한 연구 개발, 항체 특성 평가에 있어서의 기술적 진보 등을 들 수 있습니다.

향후 수년간 항체 생산 시장의 성장을 이끌 것으로 예상되는 것은 만성 질환의 유병률 상승입니다. 만성 질환은 점진적으로 진행되고 지속적인 의료 관리가 필요한 장기간의 건강 상태를 의미합니다. 이러한 질병 증가는 앉지 않은 생활이나 운동 부족 등 불활발한 생활 양식에 기인하는 부분이 크며, 심장병이나 당뇨병 등의 리스크를 높이고 있습니다. 항체 생산은 표적을 좁힌 치료 및 진단 솔루션을 제공함으로써 만성 질환 관리에 중요한 역할을 하며, 암, 자가면역 질환, 당뇨병 등의 질환 치료에 필수적입니다. 이러한 솔루션은 조기 발견과 정밀한 개입을 가능하게 하고, 치료 효과와 환자 모니터링을 향상시켜 전체 헬스케어 결과를 개선할 수 있습니다. 예를 들어, 2024년 6월에 영국 국민보건 서비스(NHS)가 발표한 데이터에 의하면, 2023년에 일반 개업의(GP)에 등록되어 있는 361만 5,330명이 비당뇨병성 고혈당(당뇨병 예비군)이라고 진단되었습니다. 이는 2022년 306만 5,825건에서 18% 증가한 것으로 나타났습니다. 그 결과, 만성 질환의 유병률의 상승이 항체 생산 시장의 성장을 가속하고 있습니다.

항체 생산 시장의 주요 기업은 연구 가속화, 협력 촉진 및 개발 기간 단축을 위해 신속 액세스 플랫폼과 같은 혁신적인 서비스 모델 개발에 주력하고 있습니다. 신속 액세스 플랫폼이란, 제휴 기업이 자사 개발 프로그램용으로 독자 기술을 신속하게 평가 및 활용할 수 있는 효율화된 서비스 제공 형태입니다. 예를 들어, 2025년 4월에는 미국 바이오테크놀러지 기업 인벤라가 'B-Body Express Service'를 시작했습니다. 본 서비스는 이 회사의 B-Body 이중특이적 항체 플랫폼에 신속하게 접근할 수 있게 하여 연구자들이 치료 발견의 초기 단계를 가속화할 수 있게 합니다. 이 서비스는 파트너 회사의 특정 관심 영역을 표적으로 하는 기능성 이중특이적 항체를 생성하는 표준화된 프로세스를 포함하며, 새로운 약물 후보의 검사 개시에 필요한 시간을 대폭 단축합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향 및 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁 및 관세, 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석 및 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도 및 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹 및 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문 및 전략

제36장 부록

AJY
영문 목차

영문목차

Antibody production is the process of generating antibodies-proteins that specifically recognize and bind to target molecules called antigens. This process involves stimulating immune cells to create highly specific antibodies for use in research, diagnostic testing, or therapeutic applications. It includes both in vivo and in vitro techniques to ensure efficient, consistent, and high-quality antibody generation.

The primary types of antibody production include monoclonal and polyclonal antibodies. Monoclonal antibodies are laboratory-produced molecules engineered to bind to a single epitope on an antigen, offering high specificity, reproducibility, and uniformity. The process involves upstream and downstream production steps and uses products such as instruments and consumables. Key end-users include pharmaceutical and biotechnology companies, research laboratories, contract research organizations (CROs), and contract development and manufacturing organizations (CDMOs).

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The antibody production market research report is one of a series of new reports from The Business Research Company that provides antibody production market statistics, including the antibody production industry global market size, regional shares, competitors with the antibody production market share, detailed antibody production market segments, market trends, and opportunities, and any further data you may need to thrive in the antibody production industry. This antibody production market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The antibody production market size has grown rapidly in recent years. It will grow from $22.29 billion in 2024 to $25.89 billion in 2025 at a compound annual growth rate (CAGR) of 16.2%. Growth in the historic period can be attributed to increasing global demand for biopharmaceuticals, the rising prevalence of infectious diseases, greater awareness of the benefits of immunotherapy, the expansion of antibody-focused research institutions, and the growing use of antibody-based diagnostics.

The antibody production market size is expected to see rapid growth in the next few years. It will grow to $46.54 billion in 2029 at a compound annual growth rate (CAGR) of 15.8%. Growth in the forecast period can be attributed to the increasing integration of automation in antibody production, a rising focus on novel therapeutic antibodies, the expansion of contract manufacturing partnerships, and growing demand from emerging markets. Major trends expected in the forecast period include innovations in antibody purification techniques, advancements in antibody-drug conjugates, developments in multi-specific antibody platforms, research and development aimed at extending antibody half-life, and technological progress in antibody characterization.

The rising prevalence of chronic diseases is expected to drive the growth of the antibody production market in the coming years. Chronic diseases are long-lasting health conditions that develop gradually and often require ongoing medical management. The increasing prevalence of these diseases is partly attributed to inactive lifestyles, where prolonged sitting and minimal physical activity increase the risk of conditions such as heart disease and diabetes. Antibody production plays a critical role in chronic disease management by providing targeted therapeutic and diagnostic solutions, making it essential for diseases like cancer, autoimmune disorders, and diabetes. These solutions improve treatment efficacy and patient monitoring by enabling early detection and precise interventions, leading to better overall healthcare outcomes. For example, in June 2024, the National Health Service (NHS) in the UK reported that 3,615,330 individuals registered with a general practitioner (GP) were diagnosed with non-diabetic hyperglycemia (pre-diabetes) in 2023, marking an 18% increase from 3,065,825 cases in 2022. As a result, the rising prevalence of chronic diseases is fueling the growth of the antibody production market.

Leading companies in the antibody production market are focusing on developing innovative service models, such as rapid-access platforms, to accelerate research, foster collaboration, and reduce development timelines. Rapid-access platforms are streamlined service offerings that allow partner companies to quickly evaluate and utilize proprietary technologies for their drug development programs. For example, in April 2025, Invenra Inc., a US-based biotechnology company, launched the B-Body Express Service. This service offers rapid access to Invenra's B-Body bispecific antibody platform, enabling researchers to speed up the early stages of therapeutic discovery. The service includes a standardized process for generating functional bispecific antibodies targeting a partner's specific interests, significantly reducing the time needed to begin testing novel drug candidates.

In March 2024, Sino Biological Inc., a China-based biotechnology company, entered into a partnership with Rapid Novor Inc. This collaboration aims to strengthen Sino Biological's custom monoclonal antibody development and production services by integrating Rapid Novor's REmAb sequencing technology. The partnership enables clients to access both accurate antibody sequence data and purified bioactive antibodies, thereby improving research efficiency. Rapid Novor Inc. is a Canada-based biotechnology company specializing in protein and antibody sequencing technologies.

Major companies operating in the antibody production market are Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., Pfizer Inc., AbbVie Inc., Bayer AG, Novartis AG, Thermo Fisher Scientific Inc., Amgen Inc., Danaher Corporation, Agilent Technologies Inc., Bio-Rad Laboratories Inc., Azenta Inc., GenScript Biotech Corporation, Sino Biological Inc., Proteintech Group Inc., Rapid Novor, Rockland Immunochemicals Inc., Biorbyt Ltd., Invenra Inc

North America was the largest region in the antibody production market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in antibody production report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the antibody production market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The antibody production market consists of sales of recombinant antibodies, humanized antibodies, antibody fragments (Fab, scFv), conjugated antibodies, and antibody kits. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Antibody Production Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on antibody production market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for antibody production ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The antibody production market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

2) By Process; Upstream Processing; Downstream Processing

3) By Product; Instruments; Consumables

4) By End Use; Pharmaceutical and Biotechnology Companies; Research Laboratories; Contract Research Organizations And Contract Development and Manufacturing Organizations

1) By Monoclonal Antibody; Mouse Monoclonal Antibody; Human Monoclonal Antibody; Rabbit Monoclonal Antibody; Rat Monoclonal Antibody

2) By Polyclonal Antibody; Rabbit Polyclonal Antibody; Goat Polyclonal Antibody; Sheep Polyclonal Antibody; Donkey Polyclonal Antibody

Table of Contents

1. Executive Summary

2. Antibody Production Market Characteristics

3. Antibody Production Market Trends And Strategies

4. Antibody Production Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Antibody Production Growth Analysis And Strategic Analysis Framework

6. Antibody Production Market Segmentation

7. Antibody Production Market Regional And Country Analysis

8. Asia-Pacific Antibody Production Market

9. China Antibody Production Market

10. India Antibody Production Market

11. Japan Antibody Production Market

12. Australia Antibody Production Market

13. Indonesia Antibody Production Market

14. South Korea Antibody Production Market

15. Western Europe Antibody Production Market

16. UK Antibody Production Market

17. Germany Antibody Production Market

18. France Antibody Production Market

19. Italy Antibody Production Market

20. Spain Antibody Production Market

21. Eastern Europe Antibody Production Market

22. Russia Antibody Production Market

23. North America Antibody Production Market

24. USA Antibody Production Market

25. Canada Antibody Production Market

26. South America Antibody Production Market

27. Brazil Antibody Production Market

28. Middle East Antibody Production Market

29. Africa Antibody Production Market

30. Antibody Production Market Competitive Landscape And Company Profiles

31. Antibody Production Market Other Major And Innovative Companies

32. Global Antibody Production Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Antibody Production Market

34. Recent Developments In The Antibody Production Market

35. Antibody Production Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기